Actively Recruiting
Real-world Data of Cardiometabolic Protection
Led by Sun Yat-sen University · Updated on 2025-06-26
40000
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are studying patients diagnosed with metabolic cardiovascular diseases such as hypertension, diabetes, obesity, dyslipidemia, and hyperuricemia. The study is a single-center, historical prospective cohort design aimed at understanding how known or suspected cardiometabolic disease risk factors relate to cardiovascular outcomes in a real-world patient group. The main focus is on measuring all-cause death and cardiovascular death, with major adverse cardiovascular events as secondary outcomes. This observational study follows patients over an average of five years to track outcomes without administering specific treatments. Researchers collect data on participants' health status and cardiometabolic disease factors to observe how these relate to mortality and cardiovascular events. There are no interventions or treatment groups, as the study observes real-world patient experiences and outcomes. Participants will be regularly monitored for their health status, including death and cardiovascular events, over the study period. The primary outcomes measured are all-cause mortality and cardiovascular death, while major adverse cardiovascular events are secondary outcomes. The study involves collecting clinical measurements and diagnoses from patient health records to evaluate disease associations and outcomes across the cohort.
CONDITIONS
Brief Title
REal-world Data of CARdiometabolic ProtEcTion
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients over 18 years old
- Clinical diagnosis of metabolic cardiovascular disease, including hypertension, diabetes, obesity, dyslipidemia, or hyperuricemia
- Hypertension or normal high blood pressure with three clinic measurements showing systolic 6 120 mmHg and/or diastolic 6 80 mmHg
- Diabetes diagnosis with typical symptoms and any of the following: random blood glucose 6 11.1 mmol/L, fasting blood glucose 6 7.0 mmol/L, OGTT 2-hour postprandial blood glucose 6 11.1 mmol/L, or HbA1c 6 6.5%
- Obesity or overweight with body mass index 6 24 kg/m8
- Dyslipidemia with abnormal lipid indicators such as total cholesterol 6 6.2 mmol/L, LDL-C 6 4.1 mmol/L, HDL-C < 1.0 mmol/L, triglycerides 6 2.3 mmol/L, or lipoprotein(a) 6 30 mg/dL
- Hyperuricemia with fasting blood uric acid levels > 420 bcmol/L (7 mg/dL) in men or > 360 bcmol/L (6 mg/dL) in women on two different days
You will not qualify if you...
- Patients unable to provide informed consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Approximately 5 years
Participants who have cardiometabolic conditions are observed over time to collect real-world data on health outcomes.
Trial Site Locations
Total: 1 location
1
The First Affiliated Hospital of Sun Yat-sen Univerity
Guangzhou, Guangdong, China, 510000
Actively Recruiting
Research Team
X
Xiaodong Zhuang
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here